PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

被引：91

作者：

Hirsch, Laure ^{[1
]}

Zitvogel, Laurence ^{[2
]}

Eggermont, Alexander ^{[3
]}

Marabelle, Aurelien ^{[1
,2
]}

机构：

[1] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces, Gustave Roussy, F-94805 Villejuif, France

[2] Univ Paris Saclay, INSERM, U1015, Gustave Roussy, F-94805 Villejuif, France

[3] Univ Paris Saclay, Gustave Roussy, F-94805 Villejuif, France

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 120卷 / 01期

关键词：

OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; SAFETY; DOCETAXEL;

D O I：

10.1038/s41416-018-0294-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

引用

页码：3 / 5

页数：3

共 50 条

[31] Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge [J].

Yang, Ying ;

Yu, Yongfeng ;

Lu, Shun .

SCIENCE CHINA-LIFE SCIENCES, 2020, 63 (10) :1499-1514

[32] Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers [J].

Strati, Areti ;

Adamopoulos, Christos ;

Kotsantis, Ioannis ;

Psyrri, Amanda ;

Lianidou, Evi ;

Papavassiliou, Athanasios G. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)

[33] Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies [J].

Chen, Meng ;

Li, Chenyan ;

Sun, Mingjun ;

Li, Yiling ;

Sun, Xuren .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[34] Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? [J].

Chae, Young Kwang ;

Pan, Alan ;

Davis, Andrew A. ;

Raparia, Kirtee ;

Mohindra, Nisha A. ;

Matsangou, Maria ;

Giles, Francis J. .

CLINICAL LUNG CANCER, 2016, 17 (05) :350-361

[35] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy [J].

Bocanegra, Ana ;

Blanco, Ester ;

Fernandez-Hinojal, Gonzalo ;

Arasanz, Hugo ;

Chocarro, Luisa ;

Zuazo, Miren ;

Morente, Pilar ;

Vera, Ruth ;

Escors, David ;

Kochan, Grazyna .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) :1-17

[36] Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade [J].

Jiang, Youhai ;

Zhao, Xiaofang ;

Fu, Jing ;

Wang, Hongyang .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[37] The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives [J].

Majidpoor, Jamal ;

Mortezaee, Keywan .

CLINICAL IMMUNOLOGY, 2021, 226

[38] PD-1/PD-L1 Inhibitors in Cervical Cancer [J].

Liu, Yuncong ;

Wu, Li ;

Tong, Ruizhan ;

Yang, Feiyue ;

Yin, Limei ;

Li, Mengqian ;

You, Liting ;

Xue, Jianxin ;

Lu, You .

FRONTIERS IN PHARMACOLOGY, 2019, 10

[39] Antagonists of PD-1 and PD-L1 in Cancer Treatment [J].

Lipson, Evan J. ;

Forde, Patrick M. ;

Hammers, Hans-Berg ;

Emens, Leisha A. ;

Taube, Janis M. ;

Topalian, Suzanne L. .

SEMINARS IN ONCOLOGY, 2015, 42 (04) :587-600

[40] Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer [J].

Mo, Dun-Chang ;

Liang, Zi-Yu ;

Chen, Long ;

Huang, Jian-Feng ;

Luo, Peng-Hui ;

Wang, Han-Lei .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (06)

← 1 2 3 4 5 →